ZLAB - Zai Lab Ltd logo

ZLAB

Zai Lab Ltd

Zai Lab Ltd develops and commercializes biopharmaceutical products targeting oncology, immunology, neuroscience, and infectious diseases, with key offerings including Zejula for ovarian cancer and VYVGART for autoimmune conditions.

โš•๏ธ Healthcare NASDAQ Listed 2017 $ USD
$1,000 invested 5 years ago โ†’$170today

Score Overview

1 Year
Score
Net Growth-7.22%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth-2.29%
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Score7.0
Net Growth73.28%
Net Trend80%
Net Income Consistencyโ€”
Rev Growth211.56%
Rev Trend80%
Revenue Consistencyโ€”
All Time
Scoreโ€”
Net Growth-273.56%
Net Trend44%
Net Income Consistency
Rev Growthโ€”
Rev Trend89%
Revenue Consistency

See the full market ranking โ†’

Zai Lab Ltd fundamental performance

Between 2020 and 2025, revenue grew from $ 48M to $ 460M and net income went from -$ 268M to -$ 175M. Revenue increased in 4 of those 5 years; net income in 4.

Zai Lab Ltd currently holds a 5-year HDB Score of 7.0 out of 10. How the HDB Score is calculated.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 25.49โ€”
1 Year2025-08-12
$ 34.31-25.71%
5 Years2021-08-12
$ 149.66-82.97%
All Time2017-09-20
$ 27.93-8.74%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 449M-$ 188M$ 617M
2025$ 460M-$ 175M$ 689M
2024$ 398M-$ 257M$ 779M
2023$ 266M-$ 334M$ 806M
2022$ 215M-$ 443M$ 1.00B
2021$ 144M-$ 704M$ 1.40B
2020$ 48M-$ 268M$ 1.18B
2019$ 12M-$ 183M$ 275M
2018$ 129.45K-$ 139M$ 263M
IPO2017$ 0.00-$ 50M$ 229M

Explore beyond ZLAB

You're looking at Zai Lab Ltd. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies